At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.
In Brief
A Phase 2 clinical trial evaluating Simvastatin, L-Arginine, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Purpose of the study: Patients with mild Alzheimer's Disease will be given three different drugs over a 4-month period to try to increase the blood flow to their brains, and improve blood vessel and brain function. Each drug can help to open the blood vessels in the brain, and together they may be more effective than each drug alone. The hypothesis is that small blood vessels secrete substances that maintain the integrity of the brain, and may prevent loss of nerve cells leading to Alzheimer's Disease
Study Details
Timeline
Interventions
Simvastatin, 40 mg per day orally
L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin 20 mg/kg/day orally